A proprietary dry-powder respiratory treatment platform

LIITA Care has developed BREATHOX®, a proprietary respiratory treatment technology that combines an established biophysical principle with engineered dry-powder delivery.

BREATHOX® delivers micronised sodium chloride directly to the respiratory surface in a compact, metered and breath-actuated format.

The technology is already commercialised in respiratory self-care and is being clinically developed for a potentially broader role in early intervention in acute respiratory tract infections.

CE-marked since 2015 | Granted IP | Published clinical evidence | Established pharmacy market experience

Explore BREATHOX®

Who we are

Familiar principle. Proprietary modality.

Sodium chloride is already widely used by healthcare professionals and consumers across respiratory care. Saline-based products form an established multi-billion-dollar global self-care category.

The therapeutic principle is familiar. What BREATHOX® changes is the exposure.

Conventional saline products deliver sodium chloride already dissolved in water. BREATHOX® delivers a high-NaCl dry-powder formulation directly to the respiratory surface, where micronised particles dissolve in the thin layer of fluid covering the airways.

This creates a transient local hyperosmotic environment and an osmotic gradient that draws water towards the airway surface, supporting mucus hydration and physiological airway clearance.

The proprietary value lies in engineering that exposure through formulation, particle characteristics, dose, deposition and breath-actuated delivery.

Explore the technology

Transforming Respiratory
Self-care

Established principle

Built on the well-established osmotic properties of sodium chloride.

Engineered exposure

Dry-powder formulation, particle engineering and controlled respiratory delivery.

Developed asset

CE market history, granted IP, clinical evidence and post-market experience.

Early RTI pathway

Clinical development towards early intervention in acute respiratory tract infections.

What We Do

From respiratory self-care to early respiratory intervention

The BREATHOX® platform extends beyond conventional saline self-care. Its local osmotic effect at the respiratory surface makes the technology relevant for investigation early in acute respiratory symptoms.

LIITA is developing this opportunity through BREATHE-RTI, a pragmatic randomised placebo-controlled primary-care programme evaluating whether early treatment can reduce symptom burden and duration and potentially reduce unnecessary antibiotic use.

If clinically validated, BREATHOX® could become a new non-pharmacological early-intervention modality between respiratory self-care and medical treatment.

Explore the evidence

Products

Dry/Wet Salt
Nasal/Oral

Indications

Antiviral
Anti-inflammatory
Pediatric

One technology. Multiple respiratory pathways.

Civilian respiratory self-care is the commercial foundation of BREATHOX®.

Civic

Its compact, power-independent and simple breath-actuated format creates potential applications in defence, preparedness and humanitarian settings.

Crisis

Relief

Defence

LIITA is evaluating these applications through selected defence innovation programmes and military medical collaborations.

These pathways provide additional strategic optionality around the core respiratory technology without changing its civilian foundation.

Our Commitment

Developed, protected and commercially tested

Explore the evidence

Our platform

Built to scale

BREATHOX® has been commercially available as a CE-marked medical device since 2015. The platform combines granted intellectual property across multiple international markets, product-specific clinical research, substantial post-market experience, established pharmacy market experience and a defined European regulatory development pathway. LIITA continues to strengthen this foundation through clinical, regulatory and commercial development aimed at international scale.

Latest News

Catch up on the latest news & updates here

05 September 2022 • Press Release

New Scientific Discovery Points Toward a Natural Solution for Mild to Moderate Covid-19 Patients

We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.

“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”

“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).

02 September 2022 • Media Update

LIITA Research to be Presented at ERS Congress 2022

We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.

“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”

“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).

Come join us Monday the 5th of September at 12.45 pm (Room 8L).

2022 • News Article